pramipexole has been researched along with granisetron in 3 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (granisetron) | Trials (granisetron) | Recent Studies (post-2010) (granisetron) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 59 | 0 | 16 |
| Protein | Taxonomy | pramipexole (IC50) | granisetron (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 4.3 | |
| D | Rattus norvegicus (Norway rat) | 3.8019 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.8019 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.8019 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.8019 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 3.8019 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 1.76 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.7702 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 5 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 1.76 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pramipexole and granisetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for pramipexole and granisetron
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |